Barbara A Bryant

US Patent:

8278038, Oct 2, 2012

Filed:

Jun 8, 2006

Appl. No.:

11/449195

Inventors:

Barbara M. Bryant - Cambridge MA, US
Andrew I. Damokosh - West Hartford CT, US
George Mulligan - Lexington MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 1/68

US Classification:

435 61

Abstract:

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

US Patent:

20030138792, Jul 24, 2003

Filed:

May 31, 2002

Appl. No.:

10/161469

Inventors:

Robert Schlegel - Auburndale MA, US
Yan Chen - Cambridge MA, US
James Deeds - Somerville MA, US
Xumei Zhao - Burlington MA, US
Barbara Bryant - Cambridge MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cervical cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of cervical cancer.

US Patent:

20030148314, Aug 7, 2003

Filed:

Aug 1, 2002

Appl. No.:

10/210314

Inventors:

Allison Berger - Watertown MA, US
Tracy Guillemette - Waltham MA, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Robert Schlegel - Auburndale MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574
C07H021/04
C12N009/00
C12P021/02
C12N005/06

US Classification:

435/006000, 435/007230, 435/069300, 435/183000, 435/320100, 435/325000, 530/388260, 536/023200

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with colon cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided.

US Patent:

20040156854, Aug 12, 2004

Filed:

Dec 4, 2003

Appl. No.:

10/728055

Inventors:

George Mulligan - Lexington MA, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew Damokosh - West Hartford CT, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

C12Q001/68
G01N033/574
A61K039/395

US Classification:

424/155100, 435/006000

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

US Patent:

20080064055, Mar 13, 2008

Filed:

Aug 9, 2007

Appl. No.:

11/891213

Inventors:

Barbara Bryant - Cambridge MA, US
Andrew Damokosh - West Hartford CT, US
George Mulligan - Lexington MA, US

International Classification:

C12Q 1/02
G01N 33/574

US Classification:

435029000, 436064000

Abstract:

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.

US Patent:

20090181393, Jul 16, 2009

Filed:

Dec 16, 2008

Appl. No.:

12/316756

Inventors:

George Mulligan - Lexington MA, US
Barbara M. Bryant - Cambridge MA, US
Michael P. Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew I. Damokosh - West Hartford CT, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435 6, 435 723

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

US Patent:

20100086922, Apr 8, 2010

Filed:

May 27, 2009

Appl. No.:

12/454944

Inventors:

Barbara M. Bryant - Cambridge MA, US
Hadi Danaee - Brookline MA, US
George J. Mulligan - Lexington MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435 6, 536 2431

Abstract:

Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.

US Patent:

20130013334, Jan 10, 2013

Filed:

Aug 31, 2012

Appl. No.:

13/600260

Inventors:

Barbara M. Bryant - Cambridge MA, US
Andrew I. Damokosh - West Hartford CT, US
George Mulligan - Lexington MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C40B 30/04
C40B 40/10
A61K 38/02
A61K 31/10
G06Q 50/22
A61K 31/4015
A61P 35/00
A61P 35/02
A61K 31/704
C40B 40/06
A61K 31/336

US Classification:

705 2, 506 9, 506 16, 506 18, 514 193, 514 196, 514710, 514475, 514423, 514 26

Abstract:

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.